Aragen CEO Subodh Deshmukh on CDMOs, Biologics & India's Biopharma Future

From leading R&D teams to becoming the CEO of one of the world's leading CDMO, his life changed. In the 12th Episode of Biologics Platform Conversations, we are joined by Dr. Subodh Deshmukh, CEO of Aragen Bioscience, a seasoned biotechnology leader with over 23 years of experience spanning product development, manufacturing, and technology operations. Throughout his career, Dr. Deshmukh has contributed to the development of several life-saving therapies while driving innovation across global pharmaceutical and biotechnology organizations. Having held senior leadership roles across large pharma, generics, and emerging biotech companies, he brings a unique perspective on transforming scientific discoveries into scalable solutions with real-world impact. Join us as we discuss the evolving biopharmaceutical landscape, innovation, manufacturing excellence, leadership, and the future of translating breakthrough science into therapies that reach patients worldwide. Chapters: 00:00 - Intro 00:53 - Who is Dr. Subodh Deshmukh? 02:28 - Aragen as the enabler of Biopharma 04:00 - Indian CDMO Ecosystem 05:06 - Globalization of Indian CDMOs 05:54 - How is Aragen gearing up for Biopharma 06:58 - How to support Emerging Modalities 07:47 - one place - accessibility 08:38 - Accelerating the Vision of @2047 09:48 - Enablers for Innovation in Biopharma 10:55 - Advice by a CEO 11:20 - RAPID FIRE!!! 11:53 - Outro Connect with us : Website: https://www.biologicsworkshop.com/ LinkedIn:   / biologics-workshop   Instagram:   / biologicsworkshop   Twitter: https://x.com/Biologics_W Youtube:    / @biologicsworkshop   Subscribe and Stay tuned for More! Disclaimer: The views expressed are those of the speaker and do not necessarily reflect those of the organizers. This content is for informational and professional purposes only. #biologics #biosimilars #academia #MumbaiBiocluster #biopharma #biotechnology #lifesciences #biomanufacturing #healthcare #innovation #biotech #ecosystem #pharma #industry #aragen #CDMO